The total study duration for participants is planned to be approximately 9 months. The study will consist of a screening visit, a baseline period (4 weeks), a 12-week double-blind treatment period, a 12-week open-label treatment period, and a follow-up period lasting approximately 3 months after the last dose of treatment.
Primary Objective:~To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.~Secondary Objectives:~To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections.~To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.